Etelcalcetide is a short synthetic peptide that switches on the calcium-sensing receptor of the parathyroid gland. That signal lowers parathyroid hormone in people with kidney failure on dialysis. This guide covers its structure, mechanism, FDA-labeled use, pivotal trials and label warnings. Sources were checked on November 17, 2026.
Quick answer: Etelcalcetide is a prescription calcimimetic peptide sold as Parsabiv by Amgen. Its label covers secondary hyperparathyroidism in adults with chronic kidney disease on hemodialysis. It has no boxed warning. The key label warnings are low blood calcium, worsening heart failure, upper gastrointestinal bleeding and adynamic bone.
Vitrapep does not sell etelcalcetide; this page is a reference summary of published research and regulatory information.
What is etelcalcetide?
The Parsabiv label calls etelcalcetide “a synthetic peptide calcium-sensing receptor agonist” (Parsabiv label, 2025). Its chemical name in the label spells out the building blocks. The backbone is seven D-amino acids: one D-cysteine, two D-alanines and four D-arginines. A separate L-cysteine is linked to the backbone through a disulfide bond.
That makes it a peptide in the plain sense: a short chain of amino acids joined by peptide bonds. D-amino acids are mirror-image forms of the usual building blocks, which enzymes break down less easily. Our peptide primer and types of peptides guide explain these terms.
PubChem lists the formula as C38H73N21O10S2 and the molecular weight as 1,048.3 g/mol (PubChem CID 71511839). The label describes the drug substance as a hydrochloride salt. Drugs@FDA lists the original approval of Parsabiv (NDA 208325) on February 7, 2017, with KAI Pharms Inc as the applicant (Drugs@FDA). Amgen is the labeler on DailyMed.
Etelcalcetide: key facts
| Fact | Detail |
|---|---|
| Structure type | Synthetic peptide: seven D-amino acids plus an L-cysteine joined by a disulfide bond |
| Class | Calcimimetic (calcium-sensing receptor agonist) |
| Molecular formula | C38H73N21O10S2 |
| Molecular weight | 1,048.3 g/mol |
| First FDA approval | February 7, 2017 (Parsabiv, NDA 208325) |
| Brand names (US) | Parsabiv (Amgen) |
How does etelcalcetide work?
The parathyroid glands release parathyroid hormone (PTH) when blood calcium falls. They sense calcium through the calcium-sensing receptor, or CaSR. In kidney failure, PTH can stay high for long periods. This is called secondary hyperparathyroidism.
The label states that etelcalcetide “is a calcimimetic agent that allosterically modulates the calcium-sensing receptor (CaSR).” It “binds to the CaSR and enhances activation of the receptor by extracellular calcium.” The label adds that activating the CaSR on parathyroid chief cells “decreases PTH secretion” (Parsabiv label, 2025). In plain terms, the gland acts as if calcium were higher than it is, so it makes less hormone.
For the hormone itself, see our guides to parathyroid hormone and the PTH analog teriparatide.
What is etelcalcetide approved for?
The Parsabiv label covers “the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis.”
The label also sets limits. Parsabiv “has not been studied in adult patients with parathyroid carcinoma, primary hyperparathyroidism, or with chronic kidney disease who are not on hemodialysis.” The label says it is not recommended in these groups.
What did the key trials show?
Two placebo-controlled trials. All of the evidence below comes from human trials. Two parallel phase 3 trials randomized 1,023 adults on hemodialysis with moderate to severe secondary hyperparathyroidism. The primary outcome was the share of patients whose PTH fell by more than 30% from baseline during weeks 20 to 27.
In trial A, 74.0% of etelcalcetide patients met that goal, compared with 8.3% on placebo. In trial B, the figures were 75.3% and 9.6%. Both differences were 65.7 percentage points (P < .001) (Block et al., 2017a). The label reports the same two studies as 77% and 79% versus 11%, using a different method for missing data. One of the registry records is NCT01788046.
Head-to-head with cinacalcet. A double-blind, double-dummy trial randomized 683 hemodialysis patients to etelcalcetide or cinacalcet, an older calcimimetic. More than a 30% drop in PTH occurred in 68.2% of etelcalcetide patients and 57.7% of cinacalcet patients. Etelcalcetide met the test for noninferiority (P < .001) and for superiority (P = .004) (Block et al., 2017b). The registry record is NCT01896232.
What side effects does the label list?
The Parsabiv label has no boxed warning. It states that the most common adverse reactions (5% or more) were “blood calcium decreased, muscle spasms, diarrhea, nausea, vomiting, headache, hypocalcemia, and paresthesia.” Paresthesia means tingling or numbness.
In the pooled placebo-controlled trials, the label reports these rates for Parsabiv versus placebo:
- Blood calcium decreased: 64% versus 10%
- Muscle spasms: 12% versus 7%
- Diarrhea: 11% versus 9%
- Nausea: 11% versus 6%
- Vomiting: 9% versus 5%
- Headache: 8% versus 6%
The label’s warnings and precautions cover four topics. They are hypocalcemia, worsening heart failure, upper gastrointestinal bleeding and adynamic bone, a low-turnover bone state (Parsabiv label, 2025).
What is etelcalcetide’s regulatory status, and how is it used in research?
Etelcalcetide is a prescription drug in the United States. Drugs@FDA lists Parsabiv with a prescription marketing status. The Parsabiv label on DailyMed, from Amgen, was last revised in January 2025.
The research described here is clinical. Amgen lists two recruiting phase 3 trials in children with secondary hyperparathyroidism on hemodialysis (NCT03969329; NCT03633708). We found no documented role for etelcalcetide as a routine laboratory reagent in the sources we checked.
Frequently asked questions about etelcalcetide
Is etelcalcetide a peptide?
Yes. The label calls it a synthetic peptide. It is a chain of seven D-amino acids with an L-cysteine attached through a disulfide bond.
When was etelcalcetide approved?
Drugs@FDA lists the original approval of Parsabiv on February 7, 2017.
How is etelcalcetide different from cinacalcet?
Both are calcimimetics that act on the calcium-sensing receptor. Etelcalcetide is a peptide, while cinacalcet is a small molecule. In a head-to-head trial, etelcalcetide met both noninferiority and superiority criteria.
Does etelcalcetide have a boxed warning?
No. Its label warnings cover low blood calcium, worsening heart failure, upper gastrointestinal bleeding and adynamic bone.
Is etelcalcetide approved for primary hyperparathyroidism?
No. The label says it has not been studied in primary hyperparathyroidism and is not recommended in that group.
What to know now
- Structure: synthetic peptide of seven D-amino acids plus a disulfide-linked L-cysteine; 1,048.3 g/mol.
- Approval: Parsabiv, February 7, 2017; prescription only.
- Mechanism: allosteric activator of the calcium-sensing receptor that lowers PTH secretion.
- Label use: secondary hyperparathyroidism in adults with CKD on hemodialysis.
- Evidence: 74.0% and 75.3% versus 8.3% and 9.6% on placebo; 68.2% versus 57.7% against cinacalcet.
- Safety: no boxed warning; low blood calcium is the most common finding.
What we’re watching
Results from Amgen’s two recruiting pediatric trials, NCT03969329 and NCT03633708, and any label change they bring. Related guides: parathyroid hormone, palopegteriparatide and teriparatide.